Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS

(REGN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 2016 2017 2018 2019 (e) 2020 (e) 2021 (e)
Sales 4 860 5 872 6 711 7 653 8 184 8 607
EBITDA 1 435 2 732 3 110 3 061 3 566 3 722
Operating profit (EBIT) 1 331 2 080 2 534 2 274 2 838 2 741
Pre-Tax Profit (EBT) 1 330 2 079 2 554 2 269 2 894 2 821
Net income 896 1 199 2 444 1 989 2 467 2 460
P/E ratio 47,7x 36,4x 17,5x 16,4x 13,6x 13,6x
EPS ( $ ) 7,70 10,3 21,3 17,4 21,0 21,1
Dividend per Share ( $ ) - - - - - -
Yield - - - - - -
Reference price ( $ ) 367,090 375,960 373,500 285,890 285,890 285,890
Announcement Date 02/09/2017
11:30am
02/08/2018
11:30am
02/06/2019
11:30am
- - -
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 2016 2017 2018 2019 (e) 2020 (e) 2021 (e)
Debt - - - - - -
Finance 56,4 706 2 101 4 884 7 627 10 477
Operating income (EBITDA) 1 435 2 732 3 110 3 061 3 566 3 722
Leverage
(Debt/EBITDA)
- - - - - -
Capital Expenditure 512 273 383 422 446 453
Free Cash Flow (FCF) 961 1 034 1 812 2 287 2 560 2 695
Book Value Per Share (BVPS) ( $ ) 42,5 57,1 76,3 110 140 170
Cash Flow per Share ( $ ) 12,7 11,3 19,1 24,4 23,6 24,3
Announcement Date 02/09/2017
11:30am
02/08/2018
11:30am
02/06/2019
11:30am
- - -
Balance Sheet Analysis
Assessed data source
© 2019 S&P Global Market Intelligence
Financial Ratios

Size 2019e 2020e
Capitalization 31 283 M $ -
Entreprise Value (EV) 26 398 M $ 23 656 M $
Valuation 2019e 2020e
P/E ratio (Price / EPS) 16,4x 13,6x
Capitalization / Revenue 4,09x 3,82x
EV / Revenue 3,45x 3,23x
EV / EBITDA 8,63x 7,40x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 2,60x 2,05x
Profitability 2019e 2020e
Operating Margin (EBIT / Sales) 29,7% 34,7%
Operating Leverage (Delta EBIT / Delta Sales) - 3,57x
Net Margin (Net Profit / Revenue) 26,0% 30,1%
ROA (Net Profit / Asset) 17,9% 17,2%
ROE (Net Profit / Equities) 23,1% 21,9%
Rate of Dividend - -
Balance Sheet Analysis 2019e 2020e
CAPEX / Sales   5,51% 5,45%
Cash Flow / Sales 34,9% 31,6%
Capital Intensity (Assets / Sales) 1,45x 1,75x
Financial Leverage (Net Debt / EBITDA) - -
EPS & Dividend